pylclari
curium pet france - piflufolastat (18f) - prostata-neoplasmen - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
bicalutamid sandoz 150 mg - filmtabletten
sandoz gmbh - bicalutamid - bicalutamid
bicalutamid hexal 150 mg - filmtabletten
hexal pharma gmbh - bicalutamid - bicalutamid
bicalutamid 1a pharma 150 mg - filmtabletten
1a pharma gmbh - bicalutamid - bicalutamid
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatahyperplasie neubildungen, kastration-resistentem - therapeutische radiopharmazeutika - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
bicalutamid-ratiopharm 150 mg filmtabletten
teva b.v. - bicalutamid - bicalutamid
bicalutamid +pharma 150 mg filmtabletten
+pharma arzneimittel gmbh - bicalutamid - bicalutamid
bicalutamid genericon 150 mg filmtabletten
genericon pharma gmbh - bicalutamid - bicalutamid
bicalutamid "interpharm" 150 mg - filmtabletten
synthon bv - bicalutamid - bicalutamid
levofloxacin 1a pharma 250 mg - filmtabletten
1a pharma gmbh - levofloxacin hemihydrat - levofloxacin